Latest Tax And Regulatory News

ANZ Group Holdings Limited has announced its 2025 final dividend of 83 cents per share, accompanied by a continuation of its Dividend Reinvestment and Bonus Option Plans offering a 1.5% discount. Shareholders have until mid-November to participate.

Betashares Capital Ltd has announced the final distribution amounts for October 2025 across multiple ETFs listed on the ASX AQUA market, alongside details on the Distribution Reinvestment Plan (DRP) and key dates for investors.

Betashares Capital Ltd has released estimated monthly distribution figures for 17 of its ETFs for the period ending October 2025, with payments scheduled for November. Investors are reminded these are preliminary figures subject to final confirmation.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Reece Limited has announced a $250 million off-market share buy-back priced between $11.00 and $13.00 per share, signaling confidence in its long-term strategy while maintaining financial flexibility.

Next Science has finalised the sale of nearly all its assets to OSARTIS GmbH for US$50 million, with plans to return approximately US$30 million net proceeds to shareholders following legal and tax review.

The Star Entertainment Group reported a statutory net loss of $471.5 million for FY25, impacted by regulatory reforms and remediation costs, while securing a $300 million strategic investment to bolster liquidity.

Strickland Metals has completed the sale of its Yandal Gold Project to Gateway Mining, distributing most Gateway shares directly to its shareholders and sharpening its focus on the Rogozna Project in Serbia.

News Corporation has announced an ordinary dividend of USD 0.10 per Class B Voting Common Stock-CDI, payable in October 2025 with key dates set for September. The dividend is unfranked and subject to withholding tax, with payments in USD and AUD depending on the security held.

BlackRock Investment Management (Australia) Limited has announced the Distribution Reinvestment Plan (DRP) prices for three major Australian iShares ETFs for the July 2025 distribution period, alongside important investor compliance reminders.

Neurizon Therapeutics has received positive feedback from the FDA on its plan to resolve the clinical hold on its ALS drug candidate NUZ-001, with key preclinical studies completed ahead of schedule. The company aims to resume clinical trials in late 2025.

BlackRock Investment Management (Australia) Limited has announced the estimated distribution components for its iShares Yield Plus ETF for the period ending 30 June 2025, revealing a total cash distribution of 70.57 cents per unit.